BACKGROUND: The Centers for Disease Control and Prevention (CDC) initiated the Colorectal Cancer Screening Demonstration Program (CRCSDP) to explore the feasibility of establishing a large-scale colorectal cancer screening program for underserved populations in the United States. The authors of the current report provide a detailed description of the total program costs (clinical and nonclinical) incurred during both the start-up and service delivery (screening) phases of the 4-year program. METHODS: Tailored cost questionnaires were completed by staff at the 5 CRCSDP sites. Cost data were collected for clinical services and nonclinical programmatic activities (program management, data collection, and tracking, etc). In-kind contributions also were measured and were assigned monetary values. RESULTS: Nearly $11.3 million was expended by the 5 sites over 4 years, and 71% was provided by the CDC. The proportion of funding spent on clinical service delivery and service delivery/patient support comprised the largest proportion of cost during the implementation phase (years 2-4). The per-person nonclinical cost comprised a substantial portion of total costs for all sites. The cost per person screened varied across the 5 sites and by screening method. Overall, economies of scale were observed, with lower costs resulting from larger numbers of individuals screened. CONCLUSIONS: Programs incur substantial variable costs related to clinical services and semivariable costs related to nonclinical services. Therefore, programs that serve large populations are likely to achieve a lower cost per person.
BACKGROUND: The Centers for Disease Control and Prevention (CDC) initiated the Colorectal Cancer Screening Demonstration Program (CRCSDP) to explore the feasibility of establishing a large-scale colorectal cancer screening program for underserved populations in the United States. The authors of the current report provide a detailed description of the total program costs (clinical and nonclinical) incurred during both the start-up and service delivery (screening) phases of the 4-year program. METHODS: Tailored cost questionnaires were completed by staff at the 5 CRCSDP sites. Cost data were collected for clinical services and nonclinical programmatic activities (program management, data collection, and tracking, etc). In-kind contributions also were measured and were assigned monetary values. RESULTS: Nearly $11.3 million was expended by the 5 sites over 4 years, and 71% was provided by the CDC. The proportion of funding spent on clinical service delivery and service delivery/patient support comprised the largest proportion of cost during the implementation phase (years 2-4). The per-person nonclinical cost comprised a substantial portion of total costs for all sites. The cost per person screened varied across the 5 sites and by screening method. Overall, economies of scale were observed, with lower costs resulting from larger numbers of individuals screened. CONCLUSIONS: Programs incur substantial variable costs related to clinical services and semivariable costs related to nonclinical services. Therefore, programs that serve large populations are likely to achieve a lower cost per person.
Authors: Uri Ladabaum; Ajitha Mannalithara; Reinier G S Meester; Samir Gupta; Robert E Schoen Journal: Gastroenterology Date: 2019-03-28 Impact factor: 22.682
Authors: Sujha Subramanian; Florence K L Tangka; Sonja Hoover; Marion Nadel; Robert Smith; Wendy Atkin; Julietta Patnick Journal: J Public Health Manag Pract Date: 2016 Sep-Oct
Authors: Kathryn E Kemper; Becky L Glaze; Casey L Eastman; Roxane C Waldron; Sonja Hoover; T'Ronda Flagg; Florence K L Tangka; Sujha Subramanian Journal: Cancer Date: 2018-10-25 Impact factor: 6.860
Authors: Karen E Kim; Fornessa Randal; Matt Johnson; Michael Quinn; Chieko Maene; Sonja Hoover; Valerie Richmond-Reese; Florence K L Tangka; Djenaba A Joseph; Sujha Subramanian Journal: Cancer Date: 2018-10-25 Impact factor: 6.860
Authors: Florence K L Tangka; Sujha Subramanian; Maggie C Beebe; Sonja Hoover; Janet Royalty; Laura C Seeff Journal: Cancer Date: 2013-08-01 Impact factor: 6.860